Overview

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Status:
Recruiting
Trial end date:
2025-05-25
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of IMM0306 in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.